{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-6ZOLYVYH/8e57cccd-e47d-4d26-b31b-4c29898c58d4/PDF","dcterms:extent":"4938 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-6ZOLYVYH/741162b3-dda8-4064-a432-358dc9e0c735/TEXT","dcterms:extent":"0 KB"}],"edm:TimeSpan":{"@rdf:about":"2011-2026","edm:begin":{"@xml:lang":"en","#text":"2011"},"edm:end":{"@xml:lang":"en","#text":"2026"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-6ZOLYVYH","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-BJTXHLKD"},{"@xml:lang":"sl","#text":"Anali PAZU"}],"dcterms:issued":"2026","dc:creator":["Maver, Tina","Maver, Uroš"],"dc:format":[{"@xml:lang":"sl","#text":"številka:1/2"},{"@xml:lang":"sl","#text":"letnik:16"},{"@xml:lang":"sl","#text":"str. 55-73"}],"dc:identifier":["DOI:10.18690/analipazu.16.1-2.55-73.2026","ISSN:2232-416X","COBISSID_HOST:288021507","URN:URN:NBN:SI:doc-6ZOLYVYH"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Univerzitetna založba Univerze v Mariboru"},"dc:subject":[{"@xml:lang":"sl","#text":"absorpcija"},{"@xml:lang":"en","#text":"absorption"},{"@xml:lang":"en","#text":"drug-drug interactions"},{"@xml:lang":"sl","#text":"Farmakokinetika"},{"@xml:lang":"sl","#text":"interakcije zdravil"},{"@xml:lang":"en","#text":"microphysiological systems"},{"@xml:lang":"sl","#text":"mikro-fiziološki sistemi"},{"@xml:lang":"sl","#text":"Staranje prebivalstva"},{"@xml:lang":"en","#text":"transdermal delivery"},{"@xml:lang":"sl","#text":"transdermalna uporaba"}],"dcterms:temporal":{"@rdf:resource":"2011-2026"},"dc:title":{"@xml:lang":"sl","#text":"Integrirani mikrofiziološki sistemi za napredne ADME modele: od absorpcijskih poti do večorganske farmakokinetike| Integrated microphysiological systems for advanced ADME modeling: from absorption routes to multi-organ pharmacokinetics|"},"dc:description":[{"@xml:lang":"sl","#text":"Despite significant advances in understanding diseases and developing new therapeutics, the translation of scientific knowledge into effective therapies remains slow and costly. A key challenge in drug development lies in the high failure rate during clinical phases, often due to the limited predictive value of preclinical models for absorption, distribution, metabolism, and excretion (ADME) properties. Traditional ADME assessment methods, including animal models and basic in vitro systems, show limited human relevance and face various limitations due to ethical, economic, and physiological considerations. The development of microphysiological systems (MPS), such as organ-on-a-chip platforms, offers a promising alternative by more accurately mimicking human tissues and organs. There is a growing need for broadly integrated platforms that simulate different absorption types related to all major application routes, including peroral (intestinal), dermal/transdermal, subcutaneous, and intravenous, while enabling functional coupling with metabolic (liver), distribution (vascular), and excretory (renal) systems. This review summarizes current trends and challenges in developing multi-organ models for MPS in ADME and drug–drug interaction studies"},{"@xml:lang":"sl","#text":"Staranje prebivalstva in vse pogostejša polifarmakoterapija pomembno povečujeta tveganje za farmakokinetične interakcije zdravil, zato je razumevanje procesov absorpcije, porazdelitve, metabolizma in izločanja (ADME) ključno za napovedovanje, preprečevanje in obvladovanje neželenih učinkov ter optimizacijo zdravljenja. Vendar pa tradicionalni predklinični pristopi, živalski modeli in klasični statični in vitro sistemi, pogosto niso ustrezni pri posnemanju človeške fiziologije bodisi zaradi medvrstnih razlik ali zaradi pomanjkanja kompleksnih medorganskih povezav. Posledica so visoke stopnje neuspeha v kliničnih fazah razvoja zdravil. Mikro-fiziološki sistemi (MPS), npr. organi na čipu predstavljajo obetavno rešitev, saj omogočajo bolj realistično posnemanje človeških tkiv in dinamičnih interakcij med organi. Za povečanje njihove relevantnosti so potrebne široko integrirane platforme, ki posnemajo poti absorpcije pri različnih poteh uporabe zdravil, na primer peroralna, dermalna/transdermalna, podkožna in intravenska, ter omogočajo funkcionalno povezavo z organi, vključenimi v metabolizem, porazdelitev in izločanje"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-6ZOLYVYH","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-6ZOLYVYH"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-6ZOLYVYH/8e57cccd-e47d-4d26-b31b-4c29898c58d4/PDF"},"edm:rights":{"@rdf:resource":"http://creativecommons.org/licenses/by-nc-nd/4.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Združenje Pomurska akademsko znanstvena unija"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-6ZOLYVYH/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-6ZOLYVYH"}}}}